Observe Medical ASA: Correction of attachments to notice of extraordinary general meeting in connection with the proposed rights issue
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
Oslo, 17 November 2023: Reference is made to the stock exchange announcement made by Observe Medical ASA (the "Company") on 1 November 2023 regarding the proposed rights issue and notice of extraordinary general meeting in connection with the rights issue. As set out in the notice, the Company has received loans from its largest shareholders, which the lenders may choose to utilize (including accrued and unaccrued interest calculated up to and including the agreed maturity date) fully or partly to set-off against the subscription amount to be paid upon any subscription of shares in the Company during the terms of the loans.
The Company has discovered an error in the calculation of interests on the abovementioned loans, and hence the total set-off amounts including interests set out in Appendix 4 to the notice of the extraordinary general meeting are not correct. A new version of Appendix 4 with corrected numbers is attached to this stock exchange announcement and made available on the Company's website https://observemedical.com/investor-relations/.
As a consequence of the above, the report from the independent expert regarding the share capital increase by conversion of debt, attached to the notice of the extraordinary general meeting as Appendix 3, has been updated to reflect the corrected amounts. A new version of Appendix 3 is attached to this stock exchange announcement and made available on the Company's website https://observemedical.com/investor-relations/.
No other changes have been made to the notice of the extraordinary meeting to be held on 22 November 2023.
For further information, please contact:
Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com
Per Arne Nygård, CFO Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A.
The Company is headquartered in Oslo, Norway, with additional offices in Narvik, Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In addition, Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.
Further information is available at www.observemedical.com.